Biotech | February 18, 2022
Sandoz launches generic lenalidomide in 19 countries across Europe
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Through this acquisition, Ayu Health will add 1000 beds to provide localised primary and tertiary medical care for citizens of Jaipur
Funding to grow the insurance and digital therapeutics vertical in India
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
Key takeaways of Q3FY22 quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
